Research ArticleOriginal Research

Prognostic Significance of Early Declines in Pulmonary Function After Allogeneic Hematopoietic Stem Cell Transplantation

Hemang Yadav, Mehrdad Hefazi Torghabeh, William J Hogan and Andrew H Limper
Respiratory Care October 2023, 68 (10) 1406-1416; DOI: https://doi.org/10.4187/respcare.10925

REFERENCES

  1. 1.↵
    1. Afessa B,
    2. Abdulai RM,
    3. Kremers WK,
    4. Hogan WJ,
    5. Litzow MR,
    6. Peters SG
    . Risk factors and outcome of pulmonary complications after autologous hematopoietic stem cell transplant. Chest 2012;141(2):442–450.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.
    1. Yadav H,
    2. Nolan ME,
    3. Bohman JK,
    4. Cartin-Ceba R,
    5. Peters SG,
    6. Hogan WJ,
    7. et al
    . Epidemiology of acute respiratory distress syndrome following hematopoietic stem cell transplantation. Crit Care Med 2016;44(6):1082–1090.
    OpenUrl
  3. 3.↵
    1. Herasevich S,
    2. Frank RD,
    3. Bo H,
    4. Alkhateeb H,
    5. Hogan WJ,
    6. Gajic O,
    7. Yadav H
    . Pretransplant risk factors can predict development of acute respiratory distress syndrome after hematopoietic stem cell transplantation. Ann Am Thorac Soc 2021;18(6):1004–1012.
    OpenUrl
  4. 4.
    1. Bellani G,
    2. Laffey JG,
    3. Pham T,
    4. Fan E,
    5. Brochard L,
    6. Esteban A,
    7. et al
    ; LUNG SAFE Investigators; ESICM Trials Group. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 2016;315(8):788–800.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Rios F,
    2. Iscar T,
    3. Cardinal-Fernandez P
    . What every intensivist should know about acute respiratory distress syndrome and diffuse alveolar damage. Rev Bras Ter Intensiva 2017;29(3):354–363.
    OpenUrl
  6. 6.↵
    1. Efrati O,
    2. Toren A,
    3. Duskin H,
    4. Modan-Moses D,
    5. Bielorai B,
    6. Goldstein G,
    7. et al
    . Pulmonary function studies in children treated by chemoradiotherapy and stem cell transplantation. Pediatr Blood Cancer 2008;51(5):684–688.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Leger P,
    2. Limper AH,
    3. Maldonado F
    . Pulmonary toxicities from conventional chemotherapy. Clin Chest Med 2017;38(2):209–222.
    OpenUrl
  8. 8.↵
    1. Wenger DS,
    2. Triplette M,
    3. Crothers K,
    4. Cheng G-S,
    5. Hill JA,
    6. Milano F,
    7. et al
    . Incidence, risk factors, and outcomes of idiopathic pneumonia syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2020;26(2):413–420.
    OpenUrl
  9. 9.
    1. Crawford SW,
    2. Fisher L
    . Predictive value of pulmonary function tests before marrow transplantation. Chest 1992;101(5):1257–1264.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.
    1. Ghalie R,
    2. Szidon JP,
    3. Thompson L,
    4. Nawas YN,
    5. Dolce A,
    6. Kaizer H
    . Evaluation of pulmonary complications after bone marrow transplantation: the role of pretransplant pulmonary function tests. Bone Marrow Transplant 1992;10(4):359–365.
    OpenUrlPubMedWeb of Science
  11. 11.↵
    1. Ho VT,
    2. Weller E,
    3. Lee SJ,
    4. Alyea EP,
    5. Antin JH,
    6. Soiffer RJ
    . Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2001;7(4):223–229.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Sorror ML,
    2. Maris MB,
    3. Storb R,
    4. Baron F,
    5. Sandmaier BM,
    6. Maloney DG,
    7. Storer B
    . Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005;106(8):2912–2919.
    OpenUrlAbstract/FREE Full Text
  13. 13.
    1. Veeraputhiran M,
    2. Yang L,
    3. Sundaram V,
    4. Arai S,
    5. Lowsky R,
    6. Miklos D,
    7. et al
    . Validation of the hematopoietic cell transplantation-specific comorbidity index in nonmyeloablative allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2017;23(10):1744–1748.
    OpenUrl
  14. 14.
    1. Raimondi R,
    2. Tosetto A,
    3. Oneto R,
    4. Cavazzina R,
    5. Rodeghiero F,
    6. Bacigalupo A,
    7. et al
    . Validation of the hematopoietic cell transplantation-specific comorbidity index: a prospective, multicenter GITMO study. Blood 2012;120(6):1327–1333.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. Sorror ML,
    2. Sandmaier BM,
    3. Storer BE,
    4. Franke GN,
    5. Laport GG,
    6. Chauncey TR,
    7. et al
    . Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. JAMA 2011;306(17):1874–1883.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Jamani K,
    2. He Q,
    3. Liu Y,
    4. Davis C,
    5. Hubbard J,
    6. Schoch G,
    7. et al
    . Early post-transplantation spirometry is associated with the development of bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2020;26(5):943–948.
    OpenUrl
  17. 17.↵
    1. Bergeron A,
    2. Chevret S,
    3. Peffault de Latour R,
    4. Chagnon K,
    5. de Margerie-Mellon C,
    6. Riviere F,
    7. et al
    . Noninfectious lung complications after allogeneic haematopoietic stem cell transplantation. Eur Respir J 2018;51(5):1702617.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Walter EC,
    2. Orozco-Levi M,
    3. Ramirez-Sarmiento A,
    4. Vigorito A,
    5. Campregher PV,
    6. Martin PJ,
    7. et al
    . Lung function and long-term complications after allogeneic hematopoietic cell transplant. Biol Blood Marrow Transplant 2010;16(1):53–61.
    OpenUrlCrossRefPubMedWeb of Science
  19. 19.↵
    1. Jagasia MH,
    2. Greinix HT,
    3. Arora M,
    4. Williams KM,
    5. Wolff D,
    6. Cowen EW,
    7. et al
    . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015;21(3):389–401.e1.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Hefazi M,
    2. Langer KJ,
    3. Khera N,
    4. Adamski J,
    5. Roy V,
    6. Winters JL,
    7. et al
    . Extracorporeal photopheresis improves survival in hematopoietic cell transplant patients with bronchiolitis obliterans syndrome without significantly impacting measured pulmonary functions. Biol Blood Marrow Transplant 2018;24(9):1906–1913.
    OpenUrl
  21. 21.↵
    1. Graham BL,
    2. Steenbruggen I,
    3. Miller MR,
    4. Barjaktarevic IZ,
    5. Cooper BG,
    6. Hall GL,
    7. et al
    . Standardization of Spirometry 2019 Update. An official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med 2019;200(8):e70–e88.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Macintyre N,
    2. Crapo RO,
    3. Viegi G,
    4. Johnson DC,
    5. van der Grinten CPM,
    6. Brusasco V,
    7. et al
    . Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26(4):720–735.
    OpenUrlAbstract/FREE Full Text
  23. 23.
    1. Miller MR,
    2. Hankinson J,
    3. Brusasco V,
    4. Burgos F,
    5. Casaburi R,
    6. Coates A,
    7. et al
    ; ATS/ERS Task Force. Standardisation of spirometry. Eur Respir J 2005;26(2):319–338.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Wanger J,
    2. Clausen JL,
    3. Coates A,
    4. Pedersen OF,
    5. Brusasco V,
    6. Burgos F,
    7. et al
    . Standardisation of the measurement of lung volumes. Eur Respir J 2005;26(3):511–522.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Thomas ET,
    2. Guppy M,
    3. Straus SE,
    4. Bell KJL,
    5. Glasziou P
    . Rate of normal lung function decline in ageing adults: a systematic review of prospective cohort studies. BMJ Open 2019;9(6):e028150.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Quanjer PH,
    2. Stanojevic S,
    3. Cole TJ,
    4. Baur X,
    5. Hall GL,
    6. Culver BH,
    7. et al
    ; ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J 2012;40(6):1324–1343.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Stanojevic S,
    2. Graham BL,
    3. Cooper BG,
    4. Thompson BR,
    5. Carter KW,
    6. Francis RW,
    7. et al
    ; Global Lung Function Initiative TLCO working group; Global Lung Function Initiative (GLI) TLCO. Official ERS technical standards: Global Lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 2017;50(3):1700010.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Scrucca L,
    2. Santucci A,
    3. Aversa F
    . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007;40(4):381–387.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.
    1. Iacobelli S
    ; EBMT Statistical Committee. Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2013;48(Suppl 1):S1–S37.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Kim HT
    . Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res 2007;13(2 Pt 1):559–565.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Austin PC,
    2. Lee DS,
    3. Fine JP
    . Introduction to the analysis of survival data in the presence of competing risks. Circulation 2016;133(6):601–609.
    OpenUrlAbstract/FREE Full Text
  32. 32.
    1. Zhang X,
    2. Zhang M-J,
    3. Fine J
    . A proportional hazards regression model for the subdistribution with right-censored and left-truncated competing risks data. Stat Med 2011;30(16):1933–1951.
    OpenUrlCrossRefPubMed
  33. 33.
    1. Lau B,
    2. Cole SR,
    3. Gange SJ
    . Competing risk regression models for epidemiologic data. Am J Epidemiol 2009;170(2):244–256.
    OpenUrlCrossRefPubMedWeb of Science
  34. 34.↵
    1. Austin PC,
    2. Fine JP
    . Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med 2017;36(27):4391–4400.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Glanville AR,
    2. Benden C,
    3. Bergeron A,
    4. Cheng G-S,
    5. Gottlieb J,
    6. Lease ED,
    7. et al
    . Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions. ERJ Open Res 2022;8(3):00185-2022.
  36. 36.↵
    1. Levy L,
    2. Huszti E,
    3. Renaud-Picard B,
    4. Berra G,
    5. Kawashima M,
    6. Takahagi A,
    7. et al
    . Risk assessment of chronic lung allograft dysfunction phenotypes: validation and proposed refinement of the 2019 International Society for Heart and Lung Transplantation classification system. J Heart Lung Transplant 2020;39(8):761–770.
    OpenUrl
  37. 37.↵
    1. Sampath S,
    2. Schultheiss TE,
    3. Wong J
    . Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 2005;63(3):876–884.
    OpenUrlCrossRefPubMed
Back to top

In this issue

 

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section

Related Articles

Cited By...

Keywords